STALEVO 200/50/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

stalevo 200/50/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 200 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

ESTROFEM estradiol (as hemihydrate) 2mg tablet dial dispenser pack Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

estrofem estradiol (as hemihydrate) 2mg tablet dial dispenser pack

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; indigo carmine; macrogol 400 - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.

ESTROFEM estradiol (as hemihydrate) 1mg tablet dial dispenser pack Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

estrofem estradiol (as hemihydrate) 1mg tablet dial dispenser pack

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 1.03 mg (equivalent: estradiol, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide red; propylene glycol - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.

STALEVO 150/37.5/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

stalevo 150/37.5/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 150 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

STALEVO 100/25/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

stalevo 100/25/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 100 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

STALEVO 50/12.5/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

stalevo 50/12.5/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 50 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

ESTROGEL estradiol (as hemihydrate) 0.06% w/w gel pump pack Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

estrogel estradiol (as hemihydrate) 0.06% w/w gel pump pack

besins healthcare australia pty ltd - estradiol hemihydrate, quantity: 0.06 % w/w (equivalent: estradiol, qty 0.06 % w/w) - gel - excipient ingredients: carbomer 980; trolamine; ethanol; purified water - - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women.,- prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (see also section 4.4 special warnings and precautions for use),the experience treating women older than 65 years is limited. the lowest effective dose should be used for the shortest duration (see sections 4.2 dose and method of administration and 4.4 special warnings and precautions for use).

ESMOLOL NORIDEM esmolol hydrochloride 100 mg/10 mL solution for  injection ampoule Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

esmolol noridem esmolol hydrochloride 100 mg/10 ml solution for injection ampoule

interpharma pty ltd - esmolol hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium acetate trihydrate; glacial acetic acid; hydrochloric acid; water for injections; sodium hydroxide; sodium chloride - supraventricular tachycardia - esmolol noridem is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol noridem is also indicated in non-compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. esmolol noridem is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

TRIDOPA levodopa/carbidopa/entacapone 150/37.5/200 mg tablet bottle Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

tridopa levodopa/carbidopa/entacapone 150/37.5/200 mg tablet bottle

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

TRIDOPA levodopa/carbidopa/entacapone 200/50/200 mg tablet bottle Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

tridopa levodopa/carbidopa/entacapone 200/50/200 mg tablet bottle

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; powdered cellulose; trehalose dihydrate; hyprolose; carmellose sodium; sodium sulfate; magnesium stearate; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.